MicroRNA-129-5p alleviates spinal cord injury in mice via suppressing the apoptosis and inflammatory response through HMGB1/TLR4/NF-κB pathway

Guang Wan¹, Yongbo An¹, Jingang Tao¹, Yanli Wang², Qinglan Zhou¹, Rongli Yang¹, Qiudong Liang¹,#

¹Department of Orthopedics, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, Henan, China; ²Operation Room, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, Henan China.

#Correspondence to: Qiudong Liang, Department of Orthopedics, The First Affiliated Hospital of Xinxiang Medical University, No.88, Jiankang Road, Weihui 453100, Henan, China. Phone/Fax: +86-0373-4404611, Email: qiudongliangqd@163.com.
Abstract

Secondary injury after spinal cord injury (SCI) is one reversible pathological change mainly involving excessive inflammatory response and neuro apoptosis. Since in recent years, microRNAs (miRNAs) have been proposed as novel regulators of inflammation in different disease conditions. However, the role of miRNAs in the inflammatory response and apoptosis of secondary injury after SCI remains to be fully elucidated. Here, we tried to explore the influence and mechanism of miRNAs on the neuron inflammatory response and apoptosis after SCI. The expression profiles of miRNA were examined using miRNA microarray, and amongst the candidate miRNAs, miR-129-5p was found the most downregulated miRNA in spinal tissues. Overexpression of miR-129-5p using agomir-miR-129-5p promoted injury mice functional recovery, suppressed the apoptosis and alleviated inflammatory response in spinal tissues. Using LPS- induced BV-2 cell model, we found miR-129-5p was also proved protecting inflammatory response and cell apoptosis in vitro. High-mobility group protein B1 (HMGB1), a well-known inflammatory mediator, was found to be directly targeted by miR-129-5p and it was associated with the inhibitory effect of miR-129-5p on the activation of TLR4/NF-κB pathway in vitro and in vivo. Further experiments revealed that the anti-apoptosis and anti-inflammatory effects of miR-129-5p were reversed by HMGB1 overexpression in BV-2 cells. Collectively, these data revealed that miR-129-5p alleviated SCI in mice via suppressing the apoptosis and inflammatory response through HMGB1//TLR4/NF-κB pathway. Our data suggest that upregulation of miR-129-5p may be a novel therapeutic target for SCI.

Keyword: Spinal cord injury, miR-129-5p, inflammatory response, HMGB1//TLR4/NF-κB pathway
Introduction

SCI is a traumatic injury that results in permanent impairment of the strength in the parts of the body served by the spinal cord below the levels of the injury. The annual incidence rate of SCI are still ~23 cases per million every year [1]. Although many therapies have been explored for the improvement of patients with SCI, all demonstrated limited efficacy thus far. SCI is characterized by primary and secondary injury. The former is irreversible physical injury to the spine, whereas the latter is a series of chemical, reversible secondary pathophysiologically changes including neuro-inflammatory response, neuronal apoptosis, and oxidative stress, worsening neurologic recovery [2-4]. Secondary injury is reversible and can be controlled. Therefore, the alleviation of neuro-inflammatory response and apoptosis can be an effective therapeutic intervention in secondary injury after SCI.

Excessive inflammatory response is a major risk factor for secondary injury after SCI [5], which can release large amounts of pro-inflammatory cytokines that ultimately result in neuronal cell death [6-11]. Previous studies have indicated that excessive inflammatory response can promote apoptosis and further aggravate secondary injury [12, 13]. However, the factors that transmit inflammatory signals after SCI have not been elucidated in detail. Currently, nuclear factor-kappa B (NF-κB) is considered as an important transcription factor of inflammatory mediators, and has been implicated in the pathophysiology of secondary SCI [14, 15]. After SCI, NF-κB is usually activated in nerve cells and microglia and promoted the secretions of inflammatory cytokines, leading to the enlargement of injury area and the damage of anatomic structures [16, 17]. High mobility group box 1 (HMGB1) is a well-known regulator in inflammatory responses. It has previously been reported that HMGB1 participates in the pathogenesis of SCI by triggering TLR4 and adaptor protein MyD88, subsequently leading to activation of NF-κB signaling and resulting in pro-inflammatory cytokines production [18]. Therefore, the suppression of the HMGB1//TLR4/NF-κB activation may be an effective strategy for treatment of SCI.

MicroRNAs (miRNAs) are single-stranded non-coding RNAs (~18-25 nucleotides in length), which typically inhibit the translation and target the degradation of mRNAs through partial complementarity [19, 20]. Numerous studies have shown the involvement of differently expressed miRNAs in the central nervous system (CNS) injury including SCI [21-23]. For example, Feng et al. showed that miR-204-5p was lowly expressed in the plasma of the SCI patients and overexpression of miR-204 improve SCI through suppressing inflammatory cytokines by targeting SOX11 in SCI mice [24]. Zhu et al. found that overexpressed miR-219-5p promoted SCI recovery and motor function elevation via alleviating NEUROD2-regulated inflammatory response in SCI mice model [25]. However, little studies paid attenuation on the functions of miRNAs in the pathophysiology of secondary damage in SCI.

In the present study, we analyzed the miRNA profiles in spinal cord tissues from a mouse SCI model. Subsequently, the improvement of neurological dysfunction, inflammatory response and apoptosis induced by miR-129-5p were verified in mice SCI models. Then, the possible mechanisms of these effects were investigated in LPS
induced BV-2 cell injury model. Our findings suggest that targeting miR-129-5p may be beneficial for preventing secondary SCI.

Materials and Methods

SCI model establishment
Adult C57BL/6 mice (8- to 10-week-old, weight 20–25 g) were obtained from Shanghai SLAC Laboratory Animal Co., Ltd (China) and housed under standard conditions (12 h light-dark cycle, 25-27°C, ~40% humidity), and had free access to food and water throughout the duration of the experiments.

Mice were anesthetized with an intraperitoneal (i.p.) injection of 50 mg/kg pentobarbital sodium (Sigma Aldrich, St. Louis, MO, USA), followed laminectomy was conducted as previously described [26]. Briefly, an incision was made in the skin, following the medial dorsal line, reaching the aponeurotic and muscular planes, and exposing the posterior vertebral arches from T8 to T12. Under dissection stereomicroscope, 3 mm long laminectomy, encompassing the caudal end of T10 vertebra and the rostral end of T11 vertebra, was performed. The Infinite Horizons impactor (Infinite Horizons, L.L.C., Lexington, KY, USA) was used in order to produce the contusion SCI using a force of 60 kdyn/cm². All animal care and experimental procedures were performed at the Animal experimental Center of Xinxiang Medical University and all procedures were approved by the Institutional Animal Care and Use Committee of The First Affiliated Hospital of Xinxiang Medical University. Sacrifice was performed by intraperitoneal injection of sodium pentobarbital (50 mg/kg) followed by cervical dislocation, and mortality was confirmed when no spontaneous breathing for 2-3 min and no blinking reflex were observed [27].

Experimental design
Mice were randomly divided into two groups: SCI and Sham group (n = 6 each group/time) were subjected to evaluate the locomotor activity using the BBB score method at 1, 3, 7, 14, 21, and 28 d after SCI. Sham 7 d, SCI 7 d (n = 6/group/time) were used to assess spared tissue, apoptosis-related protein expressions using the Cresyl violet staining, and Western Blot assay. For microarray analysis and qRT-PCR, the sample size was 3 and 5, respectively.

In another test, mice were randomly divided into four groups to determine the role of agomir-miR-129-5p: SCI group, Sham group, SCI + agomir-miR-129-5p group and SCI + agomir-negative control (NC) group. Mice were subjected to laminectomy in the SCI group (n=6/group/time), while mice underwent all surgical procedure without injury were used as Sham group. In the SCI + agomir-miR-129-5p group/agomir-NC group (n=6/group/time), the mice were subjected to laminectomy and then treated with agomir-miR-129-5p/agomir-NC (50 μL/d, 100 nmol/mL; RiboBio, Guangzhou, China) via intrathecal injection for 3 days (0, 1, and 2 days) starting 15 min after SCI. After 4 weeks, mice were humanely sacrificed with intraperitoneal injection of 50 mg/kg pentobarbital sodium followed by cervical
dislocation, and subsequently, the injury spinal cord and serum were harvested for further experiments. The sequences of agomir-miR-129-5p and agomiR-NC as follows: agomir-miR-129-5p 5′-CUUUUUGCGGUCUGGCUCUUGC-3′ (sense), 5′-AAGCCACGACCGAAAAAGUU-3′ (antisense) and agomiR-NC 5′-UUCUCCGAACGUGACACGUTT-3′ (sense), 5′-ACGUGACACGUCCAGAATT-3′ (antisense).

**Basso, Beattie and Bresnahan (BBB) score**

BBB score was performed to test locomotor function of mice after SCI using the as described previously [28], which comprise 21 different criteria for the movement of lower limbs, from complete paralysis to complete mobility. These criteria are based on the accurate observation of the lower limbs, including movement, step, and coordinated motor action. The scores were recorded by two well-trained investigators who were blind to the experiments.

**Cresyl violet staining**

Cresyl violet stain was used for staining myelinated axons and the Nissl substance to assess spared myelin volume surrounding the lesion in the injury cord. The spared tissue area was measured using Cresyl violet staining as described previously [29]. Briefly, spinal cord from indicated groups were fixed with 4% paraformaldehyde (PFA) and embedded in paraffin. Tissue sections (10 μm) were subjected to cresyl violet staining, and the lesion was evaluated by ImageJ version 1.46 (Rawak Software, Inc. Munich, Germany).

**Spinal cord water content measurement**

The spinal cord tissues obtained in the above experimental procedure at 7 days post-injury were immediately weighted, and then the dry weight of spinal cord tissues was obtain at 70-80°C for 48 h. The ratio of wet-to-dry weight calculated as follows: [(wet weight - dry weight)/wet weight] ×100%.

**Immunohistochemical (IHC) and immunofluorescent analysis (IFA)**

For IHC, the spinal cord segments were paraffin-embedded and cut into 5-µm-thick slides. Next, the tissue sections were deparaffinized and dehydrated through graded alcohols. The slices were then incubated in 3% H₂O₂ for 15 min at room temperature, and then blocked in 10% bovine serum for 30 min. Next, the slices were stained overnight at 4°C with a primary antibody against cleaved caspase-3 (cat. no. 9661, Cell Signaling Technology, Inc, 1:200). Subsequently, the sections were incubated with secondary antibodies (cat. no. 7074; Cell Signaling Technology, Inc. 1:2,000). Finally, the immunoreactivity was visualized by staining with dianaminobenzidine (DAB) for 3 min, covered with a cover-slip, and analyzed under a light microscope (BX51, Olympus Inc., Tokyo, Japan) at 200× magnification. ImageJ version 1.46 (Rawak Software, Inc. Munich, Germany) was used to quantify IHC staining.

For IFA, the BV-2 cells were washed twice with PBS and fixed with 4%
paraformaldehyde for 15 minutes then blocked with 5% BSA for 1 hour at room temperature. Then, the cells were incubated with primary antibodies of cleaved caspase-3 (cat. no. 9661, Cell Signaling Technology, Inc, 1:1000) at 4 °C overnight. The next day, after incubation with fluorescent secondary antibodies (Invitrogen) for 1 hour, the cells were observed under a fluorescent microscope (Olympus Inc., Tokyo, Japan). ImageJ version 1.46 (Rawak Software, Inc. Munich, Germany) was used to quantify fluorescent staining.

**ELISA assay**

The levels of IFN-α (cat no.42120-1), Mouse IL-1β (cat no. 42400-1), IL-6 (cat no.D6050) and IL-10 (cat no.DY417) in mice serum and cell supernatants were measured using ELISA kit (all from R&D Systems, Minneapolis, MN) according to the manufacturer’s protocol. Absorbance was detected using an automatic multi-well spectrophotometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 450 nm.

**miRNA microarray assay**

Total RNA was isolated from spinal cord tissues using RNAEasy plus kit (Qiagen) according to the manufacturer's protocol. The RNA was quantified by NanoDrop ND-1000 spectrophotometry (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Total RNA (200 ng) was labeled with fluorescence dye hy3 or hy5 using the miRCURY Hy3/Hy5 Power Labeling kit and hybridized on the miRCURY™ LNA array (v.16.0; Exiqon A/S, Copenhagen, Denmark), which were designed based on miRBase release 10.0 and contained 546 probes from humans, mice and rats. The procedure and imaging processes were as described previously [29].

**RNA isolation and quantitative RT-PCR**

Total RNA from spinal cord tissues and cells was isolated using TRIzol reagent (TaKaRa, Dalian, China). Reverse transcription of miR-129-5p was synthesized using the miScript II RT kit (Invitrogen, Carlsbad, CA), and cDNA of mRNA was synthesized by using an iScript cDNA synthesis kit (Bio-Rad). For miR-129-5p, the qRT-PCR assays were carried out using a miRNA qPCR detection kit (Tiangen, Beijing). For mRNA, qRT-PCR was conducted by SYBR-Green Gene Expression Assay kit (Tiangen, Beijing) and performed on an ABI Prism 7900 HT (Applied Biosystems). The primers used for were as follows: miR-129-5p F 5’-GGGGGCTTTTTGCGGTCTGG-3’, R: 5’-AGTGCGTGTCGAGTC-3’; U6 F: 5’-GCTTCGGACACATATACATAAAAAT-3’, R 5’-CGCTTCAGAATTTGCTGCAT-3’; HMBG1 F 5’-AGGCTGACACGGCTCGTATG-3’, R 5’-TATCATCAGCGAGCTTG-3’; GAPDH F, 5’-GAAGATGGTGATGGGATTTC-3’, and R, 5’-AACGCTTCAATTGTCTG-3’. The relative expression of each gene was calculated using the 2^ΔΔCt method [30].

**Cell culture and treatment**

Immortal BV-2 murine microglial cells treated with LPS were widely used to
induce cell injuries to mimic the in vitro model of SCI [31]. The BV-2 cell line was obtained from ATCC (Manassas, VA, USA) and maintained in DMEM/F12 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% FBS (Gibco), and 1% penicillin and streptomycin (Sigma-Aldrich, St. Louis, MO, USA) in 5% CO\textsubscript{2} at 37°C.

BV-2 cells were treated with LPS (Sigma-Aldrich, St Louis, MO, USA) at a concentration of 100 ng/mL for 4 h at 37°C as previously reported [32].

**Cell transfection**

When BV-2 cells grown to about 80% confluence in six-well plate, 20 nM agomiR-129-5p or 2 μg pcDNA-HMGB1 were transfected into cells at 37°C for 48 h, using Lipofectamine\textsuperscript{®} 2000 (Invitrogen). The agomir-miR-129-5p and agomiR NC, were obtained from RiboBio (Guangzhou, China). HMGB1 overexpressing vector pcDNA-HMGB1 was also constructed by RiboBio (Guangzhou, China).

**Caspase-3 activity**

After treatment, the activity of caspase-3 in cell lysates was evaluated using a Caspase-3 Activity Assay kit (Beyotime Institute of Biotechnology), according to the manufacturer’s protocol. The OD value was then measured using a Multiskan Sky microplate reader at an absorbance of 405 nm.

**Luciferase reporter assay**

pGL3-HMGB1 wide type (Wt) or pGL3-HMGB1 mutant type (mut) plasmids were co-transfected with 20 nM agomiR-129-5p into BV-2 cells in 24-well plates (2 × 10\textsuperscript{5} cells/well) using Lipofectamine 2000 reagent (Invitrogen). At 48 h post-transfection, luciferase activity was analyzed using the Dual-Luciferase Reporter Assay system (Promega Corporation) and normalized to Renilla luciferase activity.

**Western blot**

Western blot was performed as previously described [31]. Briefly, spinal cord tissues and cells were lysed in radio immunoprecipitation assay buffer (Cell Signaling Technology), and protein concentrations were determined by using bicinchoninic acid assays (Cell Signaling Technology). 40 μg extracted protein samples were separated on SDS-PAGE gels and transferred onto a PVDF (Millipore) membrane, and blocked with 5% skim milk for 2 h at room temperature (RT). Then, the membrane was incubated with primary antibodies against HGMB1 (cat no. 6893), TLR4 (cat no. 14358), cleaved-caspase-3 (cat. no. 9661), nuclear p-p65 (cat. no. 3033), p65 (cat. no. 8242), Bax (cat. no. 14796), Bcl-2 (cat. no. 4223), cleaved PARP (cat. no. 5625) and β-actin (cat. no. 4970) at 4 °C overnight. All antibodies were obtained from Cell Signaling Technology, Inc and the dilution was 1:1000. Subsequently, the blot was incubated with appropriate secondary antibodies (cat. no. 7074; Cell Signaling Technology, Inc. 1:2,000) for 1 h at RT. The results were detected using ECL kit (GE Healthcare) and analyzed with ImageJ version 1.46 (Rawak Software, Inc. Munich, Germany).
Statistical analysis

Statistical analysis was conducted using GraphPad Prism (version 5.0, Inc., La Jolla, CA, USA). Data were recorded as means ± SD. Differences between groups were analyzed using one way ANOVA or Student’s t-test. A p value < 0.05 was considered significant.

Results

miR-129-5p was downregulated in spinal cord of SCI mice

Firstly, a mice model of SCI injury was established as previously described [26], and then the behavioral analyses of mice were evaluated. As shown in Figure 1A, a spontaneous functional recovery was observed in SCI mice during the experiment, but BBB scores were significantly lower in SCI group than that in the Sham group. Cresyl violet staining was used to assess spared tissue following behavioral analyses. Sections of thoracic spinal cord were analyzed and the ratio for “injured area/total area” from each section determined. The spared tissue was smaller in SCI mice not only at the injury epicenter, but also in regions extending away from the epicenter, in both rostral and caudal directions, compared with Sham group (Figure 1B). Spinal cord edema was evaluated by detecting water content of spinal cord. It was observed that water contents in spinal cord were significantly increased compared with Sham group and was maximal at 7 days (Figure 1C). All data indicated SCI model was successfully constructed.

Subsequently, a microRNA array was used to analyze miRNA profiles in SCI tissues; it was found that 19 miRNAs were significantly decreased and 36 miRNAs were increased in SCI group, compared to Sham group (Figure 1D). In our microarray data, miR-494 and miR-210 was decreased while miR-21 was increased, which is consistent with previous reports [29, 33, 34], suggesting the reliability of our microarray results. But, in our study, miR-129-5p exhibited the most downregulated alteration in spinal tissues of SCI mice. Notably, a recent study performed by Li et al. reported that miR-129-5p prevented the neuroinflammation and blood-spinal cord barrier damage in spinal cord [35]. However, whether miR-129-5p can exert protective effects against inflammatory response and apoptosis in secondary SCI remains unclear. Therefore, we chose miR-129-5p for further investigation. Next, the expression change of miR-129-5p was calculated in spinal cord tissues of mice at different time points. As shown in Figure 1E, the miR-129-5p expression levels were reduced at different time points after SCI compared to the expression in the sham group. The decrease in level of expression of miR-129-5p was minimal at 7 days post injury and then its expression was gradually increased until 28 days after injury. All data indicates that miR-129-5p may be involved in the pathogenesis of SCI.

Agomir-miR-129-5p injection improved functional recovery and suppressed neurons apoptosis

To examine the impact of miR-129-5p in SCI, agomir-miR-129-5p and agomiR-NC were intrathecially injected into SCI mice. miR-129-5p expression level
was significantly increased in spinal cord of SCI mice from 1 to 28 d post injury, compared to agomiR-NC group (Figure 2A). Subsequently, the hindlimb motor function recovery of SCI mice was evaluated using BBB score. Agomir-miR-129-5p injection indeed improved functional recovery from 3 days compared with that in the agomir-NC injection group (Figure 2B). Using cresyl violet staining assay, it was found that the amount of spared tissue was markedly increased in SCI + agomir-miR-129-5p group compared with the agomir-NC-treated SCI mice, indicating that agomir-miR-129-5p can reduce lesion size in SCI mice (Figure 2C). Meanwhile, the water contents in spinal cord were found to be dramatically decreased after administered with agomir-miR-129-5p, compared with the agomir-NC-treated SCI mice group (Figure 2D), suggesting the alleviation of spinal cord edema. To test whether apoptosis accounted for the protection of miR-129-5p against SCI, the cleaved-caspase-3 expression was measured by immunohistochemistry staining. As shown in Figure 2E, SCI resulted in a significant increase in the expression of cleaved-caspase-3 compared to Sham group, while agomir-miR-129-5p significantly reduced SCI induced expression of cleaved-caspase-3 in spinal cord tissues. Furthermore, Western Blot was used to detect the expression of Bcl-2, Bax, cleaved-caspase-3 and cleaved-PARP in spinal cord tissues following agomir-miR-129-5p treatment. As expected, agomir-miR-129-5p markedly increased the expression level of Bcl-2, and decreased the expression levels of Bax, cleaved-caspase-3 and cleaved-PARP compared with agomir-NC-treated SCI mice (Figure 2F). Taken together, miR-129-5p upregulation could promote functional recovery and protect neurons against SCI induced apoptosis in mice.

**Agomir-miR-129-5p injection inhibited the inflammatory response in SCI mice**

To further evaluate the influence of antagomiR-129-5p on the inflammatory response, the releases of TNF-α, IL-6, IL-1β and IL-10 in serums of SCI mice were detected by ELISA. As shown in Figure 3A-D, the expression levels of TNF-α, IL-6, IL-1β were significantly increased, and IL-10 was markedly decreased compared to the Sham group. However, miR-129-5p upregulation significantly reduced the expressions of these pro-inflammatory cytokines, while enhanced the levels of IL-10 induced by SCI. These data indicated that agomir-miR-129-5p suppressed the SCI induced inflammatory response in mice.

**Overexpression of miR-129-5p suppressed apoptosis and inflammatory response in LPS treated BV-2 cells**

In order to explore the molecular mechanism involved in the protection of miR-129-5p in secondary SCI induced apoptosis and inflammatory response, we established a SCI cell model using LPS-treated BV-2 cells as previously described [36]. Following various concentrations of LPS (10-1000ng/ml) treatment, miR-129-5p was significantly downregulated compared to control group in BV-2 cells (Figure 4A). And no differences were detected between the two groups of cells treated with 100 and 1000 ng LPS. Thus, 100 ng/ml LPS was selected as the appropriate concentration in the subsequent experiments, which is also consistent with a previous study [37]. To
investigate the functions of miR-129-5p in LPS-induced BV-2 cell injury, the agomir-miR-129-5p was added to BV-2 cells 4 h prior to LPS treatment. qRT-PCR assay showed that miR-129-5p was notably increased after agomir-miR-129-5p treatment in BV-2 cells (Figure 4B). Functional experiments revealed that agomir-miR-129-5p markedly reduced LPS induced the activity of caspase-3 and the expression of caspase-3, determined as using caspase-3 activity assay and IFA assay in BV-2 cells, respectively (Figure 4C, D). Additionally, the impact of miR-129-5p on the expression levels of inflammatory cytokines was further assayed. As expected, agomir-miR-129-5p treatment markedly inhibited the expression levels of TNF-α, IL-6, IL-1β, but promoted the expression of IL-10 in LPS plus agomir-miR-129-5p, compared with LPS plus agomir-NC group (Figure 4E-H). All data suggest that miR-129-5p upregulation improved the LPS-induced BV-2 cell injury.

**HMGB1 is a direct target of miR-129-5p in BV-2 cells**

To explore the potential mechanisms in which miR-129-5p protected BV-2 cells against LPS induced apoptosis and inflammatory response, we performed TargetScan 7.0 and miRanda to predict the targets of miR-129-5p. Bioinformatic analysis indicated high mobility group box 1 (HMGB1) was a potential target of miR-129-5p (Figure 5A). Previous studies have reported that HMGB1 plays an amplifying role in tissue pathology and inflammation, leading to secondary damage after the initial SCI [38, 39]. Thus, we chose it for next study. Next, luciferase reporter assay was then performed in BV-2 cells to determine whether miR-129-5p directly targets HMGB1. As shown in Figure 5B, agomir-miR-129-5p significantly repressed the luciferase activity of the HMGB1-3'UTR wt reporter plasmid, but not that of the mutant reporter. Furthermore, the results of Western Blot analysis showed that agomir-miR-129-5p notably reduced protein levels of HMGB1 in BV-2 cells (Figure 5C). It was also observed that the mRNA levels of HMGB1 were significantly upregulated in BV-2 cells following LPS challenge (Figure 5D), which is consistent with a previous study [40].

HMGB1 signaling through multiple receptors, such as toll-like receptor-4 (TLR4) promotes activation of the nuclear factor-kappa B (NF-κB) transcription factor, which is directly related to inflammatory response in secondary SCI [39, 41]. Further studies were designed to examine the influence of miR-129-5p on the activation of TLR4/NF-κB *in vitro*. The results showed that LPS induced the expressions of HMGB1, TLR4 and p-p65 at protein levels, whereas agomir-miR-129-5p overexpression reversed these promoting effects of LPS in BV-2 cells (Figure 5E). All these results indicated that the miR-129-5p inhibited the inflammation via HMGB1/TLR4/NF-κB pathway.

**miR-129-5p protects BV-2 cells from LPS-induced apoptosis and inflammatory response by targeting HMGB1**

Given the indispensable role of HMGB1 in the inflammatory response following SCI, we tried to determine whether HMGB1 mediated the protective effects of miR-129-5p on the inflammation in SCI. We transfected HMGB1 expression vector,
pcDNA-HMGB1, together with agomir-miR-129-5p into BV-2 cells 4 h prior to LPS treatment. It was found that the protein expression of HMGB1 was significantly increased after pcDNA-HMGB1 transfection in BV-2 cells (Figure 6A). Functionally, agomir-miR-129-5p treatment inhibited the caspase-3 expression and the caspase-3 activity in LPS treated BV-2 cells, whereas overexpression of HMGB1 by pcDNA-HMGB1 attenuated the inhibitory effect of miR-129-5p on the protein expression of caspase-3 and caspase-3 activity (Figure 6B, C). Furthermore, inflammatory cytokine productions were evaluated using ELISA in LPS-treated BV-2 cells following pcDNA-HMGB1 and agomir-miR-129-5p co-transfection. As shown in Figure 6D-G, agomir-miR-129-5p treatment markedly decreased TNF-α, IL-6, IL-1β protein expression levels and increased the IL-10 expression in LPS-treated BV-2 cells, while these effects of agomir-miR-129-5p was reversed by overexpression of HMGB1. These data suggest that miR-129-5p protects BV-2 cells from LPS-induced apoptosis and inflammatory response by targeting HMGB1, indicating agomir-R-129-5p may improve secondary SCI through HMGB1/TLR4/NF-κB pathway.

Discussion

In the present study, miR-129-5p was found to be significantly downregulated in spinal cord tissues of SCI mice and LPS induced BV-2 cell injury model. Agomir-miR-129-5p injection improved the functional recovery and reduced the spared tissues and water content of spinal cord in SCI mice. Moreover, miR-129-5p overexpression inhibited SCI induced inflammatory response in vivo and in vitro. Notably, the data indicated that the overexpression of miR-129-5p may exert protective effects by blocking HMGB1/TLR4/NF-κB pathway activation. Our findings could provide a new guidance for the improvement of SCI patients in the future.

A number of studies demonstrated that miRNAs are aberrantly expressed in SCI, and may influence secondary SCI pathophysiology, such as inflammation and apoptosis [24, 42, 43]. For example, Xu et al found that miR-124 improved functional recovery and suppressed neuronal cell apoptosis by blocking the mitochondrial apoptotic pathway in SCI rats [44]. Feng et al. found that miR-204-5p level in the SCI mice was decreased, and overexpression of miR-204-5p restored upper and lower limb strength of mice by suppressing inflammation below the injury site [24]. Another study performed by Xu et al. reported that miR-124 may improve functional recovery and suppress neuronal cell apoptosis by blocking the mitochondrial apoptotic pathway in SCI mice [44]. In the present study, using a miRNA microarray, we found large numbers of miRNAs were significantly deregulated; in particular, miR-129-5p was identified as the most downregulated miRNA in spinal cord tissues from SCI mice, suggesting miR-129-5p may be involved in secondary injury.

Several studies have shown that miR-129-5p acts as a novel regulator of the inflammatory response and apoptosis in various inflammatory diseases. For example, Li et al. reported that miR-129-5p suppressed the spinal cord ischemia-reperfusion (IR)
injury induced inflammation in mice by inhibiting HMGB1 and the TLR3-cytokine pathway [35]. Notably, Zou et al. showed that miR-129-5p overexpression inhibited the inflammation and apoptosis in palmitic acid (PA) induced cardiomyocyte injury model [45]. As we known, apoptosis is another key process that influences the development of neuronal tissue damage following SCI [13]. Therefore, it was hypothesized that miR-129-5p may affect the secondary injury through the regulation of inflammation and apoptosis. In our study, we found that agomir-miR-129-5p injection could improve the functional recovery, reduced spared tissue and edema of spinal cord, and suppressed the inflammatory response and apoptosis in mice, indicating the miR-129-5p has a protection effect in secondary SCI by inhibiting neuronal cell inflammation and apoptosis. However, the underlying molecular mechanisms involved in miR-129-5p mediated inflammation and apoptosis suppression have not been completely clarified.

HMGB1 is a well-known regulator in inflammatory responses [46, 47]. It can be actively secreted from reactive astrocytes and microglia after pathogenic insult or tissue injury [48]. Extracellular HMGB1 triggers inflammatory responses through the activation of multiple receptors, such as toll-like receptors (TLRs) in immune-competent cells, neurons, and astrocytes [49, 50]. HMGB1 signaling through these receptors activated NF-κB transcription factor, which is required for the expression of the many mediators of inflammatory responses and cell survival, such as TNF-α, IL-1, and IL-6 [51]. HMGB1 has been shown to be upregulated in several pre-clinical models of SCI, where it promotes the accrualment of secondary injury [40]. Kang et al. showed that inhibition of HMGB1/TLR4/NF-κB signaling pathway improved the functional recovery of SCI rats [52]. Interestingly, several studies reported that miR-129-5p has a tumor suppressive role by targeting HMBG1 in various human cancers [53, 54]. Of note, Liu et al. showed that miR-129-5p suppressed the progress of autoimmune encephalomyelitis (AE)-related epilepsy by inhibiting HMGB1/TLR4/NF-κB pathway [55]. In our study, HMGB1 was proved to be a target of miR-129-5p in BV-2 cells and its expression was increased in LPS treated BV-2 cells. Moreover, our data showed that miR-129-5p reduced the levels of key TLR4/NF-κB pathway proteins by suppressing HMGB1. Furthermore, we found that overexpression of HMGB1 reversed the inhibitory effects of miR-129-5p on LPS induced inflammatory response and apoptosis in BV-2 cells. All data suggest that miR-129-5p suppressed HMGB1 to blocked the TLR4/NF-κB pathway activation and therefore repressed the LPS induced inflammatory response and apoptosis.

In conclusion, our data showed that miR-129-5p improved secondary damage and facilitate functional recovery through inhibiting inflammatory responses via inactivation of the HMGB1/TLR4/NF-κB pathway in SCI mice model. Our findings may provide a novel direction for the therapeutics of SCI.

Acknowledgments: This study was supported by the talent project of the First Affiliated Hospital of Xinxiang Medical University (No: 20170696).
Conflict of Interest: We have no conflict of interest to declare.

Authors’ contribution: Conceived and designed the experiments: Qiudong Liang. Performed the experiments: Guang Wan, Yongbo An, Jingang Tao, Yanli Wang, Qinglan Zhou and Rongli Yang. Analyzed the data: Guang Wan, Yongbo An, Jingang Tao, Yanli Wang, Qinglan Zhou and Rongli Yang. Contributed reagents/materials/analysis tools: Qiudong Liang. Wrote the paper: Qiudong Liang. All authors have read and agreed to the final version of manuscript.

References
[1] Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, Lin W, Huang Q, Li G, Zheng J, Chang C: LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ 2017, 24(9): 1502-1517.
[2] Goldshmit Y, Kanner S, Zacs M, Frisca F, Pinto AR, Currie PD, Pinkas-Kramarski R: Rapamycin increases neuronal survival, reduces inflammation and astrocyte proliferation after spinal cord injury. Mol Cell Neurosci 2015, 68 82-91.
[3] Blight AR: Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent Nerv Syst Trauma 1985, 2(4): 299-315.
[4] Orr MB, Gensel JC: Spinal Cord Injury Scarring and Inflammation: Therapies Targeting Glial and Inflammatory Responses. Neurotherapeutics 2018, 15(3): 541-553.
[5] Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD, Yezierski RP: Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 1998, 18(9): 3251-60.
[6] Qin S, Yang C, Huang W, Du S, Mai H, Xiao J, Lu T: Sulforaphane attenuates microglia-mediated neuronal necroptosis through down-regulation of MAPK/NF-kappaB signaling pathways in LPS-activated BV-2 microglia. Pharmacol Res 2018, 133 218-235.
[7] Zhou HJ, Wang LQ, Wang DB, Yu JB, Zhu Y, Xu QS, Zheng XJ, Zhan RY: Long noncoding RNA MALAT1 contributes to inflammatory response of microglia following spinal cord injury via the modulation of a miR-199b/IKKbeta/NF-kappaB signaling pathway. Am J Physiol Cell Physiol 2018, 315(1): C52-C61.
[8] Ning SL, Zhu H, Shao J, Liu YC, Lan J, Miao J: MiR-21 inhibitor improves locomotor function recovery by inhibiting IL-6R/JAK-STAT pathway-mediated inflammation after spinal cord injury in model of rat. Eur Rev Med Pharmacol Sci 2019, 23(2): 433-440.
[9] Harrington JF, Messier AA, Levine A, Szmydynger-Chodobska J, Chodobski A: Shedding of tumor necrosis factor type 1 receptor after experimental spinal cord injury. J Neurotrauma 2005, 22(8): 919-28.
[10] Lee YB, Yune TY, Baik SY, Shin YH, Du S, Rhim H, Lee EB, Kim YC, Shin ML, Markelonis GJ, Oh TH: Role of tumor necrosis factor-alpha in neuronal and glial apoptosis after spinal cord injury. Exp Neurol 2000, 166(1): 190-5.
[11] Yune TY, Chang MJ, Kim SJ, Lee YB, Shin SW, Rhim H, Kim YC, Shin ML, Oh YJ, Han CT, Markelonis GJ, Oh TH: Increased production of tumor necrosis factor-alpha induces apoptosis after traumatic spinal cord injury in rats. J Neurotrauma 2003, 20(2): 207-19.

[12] Bank M, Stein A, Sison C, Glazer A, Jassal N, McCarthy D, Shatzer M, Hahn B, Chugh R, Davies P, Bloom O: Elevated circulating levels of the pro-inflammatory cytokine macrophage migration inhibitory factor in individuals with acute spinal cord injury. Arch Phys Med Rehabil 2015, 96(4): 633-44.

[13] Kawabata H, Setoguchi T, Yone K, Souda M, Yoshida H, Kawahara K, Maruyama I, Komiya S: High mobility group box 1 is upregulated after spinal cord injury and is associated with neuronal cell apoptosis. Spine (Phila Pa 1976) 2010, 35(11): 1109-15.

[14] Feng L, Ma J, Ji H, Liu Y, Hu W: miR-330-5p suppresses glioblastoma cell proliferation and invasiveness through targeting ITGA5. Biosci Rep 2017, 37(3).

[15] Chen X, Wu S, Chen C, Xie B, Fang Z, Hu W, Chen J, Fu H, He H: Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-kappaB pathway following experimental traumatic brain injury. J Neuroinflammation 2017, 14(1): 143.

[16] Brambilla R, Bracchi-Ricard V, Hu WH, Frydel B, Bramwell A, Karmally S, Green EJ, Bethea JR: Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J Exp Med 2005, 202(1): 145-56.

[17] Jimenez-Garza O, Camacho J, Ibarra A, Martinez A, Guizar-Sahagun G: Early effects of modulating nuclear factor-kappaB activation on traumatic spinal cord injury in rats. Ann N Y Acad Sci 2005, 1053 148-50.

[18] da Silva JR, da Silva ML, Prado WA: Electroacupuncture at 2/100 hz activates antinociceptive spinal mechanisms different from those activated by electroacupuncture at 2 and 100 hz in responder rats. Evid Based Complement Alternat Med 2013, 2013 205316.

[19] Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10(10): 704-14.

[20] Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2): 215-33.

[21] Liu NK, Wang XF, Lu QB, Xu XM: Altered microRNA expression following traumatic spinal cord injury. Exp Neurol 2009, 219(2): 424-9.

[22] Liu G, Keeler BE, Zhukareva V, Houle JD: Cycling exercise affects the expression of apoptosis-associated microRNAs after spinal cord injury in rats. Exp Neurol 2010, 226(1): 200-6.

[23] Zhai F, Zhang X, Guan Y, Yang X, Li Y, Song G, Guan L: Expression profiles of microRNAs after focal cerebral ischemia/reperfusion injury in rats. Neural Regen Res 2012, 7(12): 917-23.

[24] Feng JS, Sun JD, Wang XD, Fu CH, Gan LL, Ma R: MicroRNA-204-5p targets SOX11 to regulate the inflammatory response in spinal cord injury. Eur Rev Med Pharmacol Sci 2019, 23(10): 4089-4096.
MiR-219-5p promotes spinal cord injury recovery by inhibiting NEUROD2-regulated inflammation and oxidative stress. Eur Rev Med Pharmacol Sci 2019, 23(1): 37-43.

Interaction of reactive astrocytes with type I collagen induces astrocytic scar formation through the integrin-N-cadherin pathway after spinal cord injury. Nat Med 2017, 23(7): 818-828.

Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway. International journal of oncology 2019, 55(4): 879-895.

A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995, 12(1): 1-21.

Anti-apoptotic effect of microRNA-21 after contusion spinal cord injury in rats. J Neurotrauma 2013, 30(15): 1349-60.

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4): 402-8.

Downregulation of miR-199b promotes the acute spinal cord injury through IKKbeta-NF-kappaB signaling pathway activating microglial cells. Exp Cell Res 2016, 349(1): 60-67.

miRNA-146a attenuates inflammation in an in vitro spinal cord injury model via inhibition of TLR4 signaling. Exp Ther Med 2018, 16(4): 3703-3709.

SIRT1 inhibits apoptosis in in vivo and in vitro models of spinal cord injury via microRNA-494. Int J Mol Med 2019, 43(4): 1758-1768.

MiR-363-3p inhibits the epithelial-to-mesenchymal transition and suppresses metastasis in colorectal cancer by targeting Sox4. Biochem Biophys Res Commun 2016, 474(1): 35-42.

High-throughput proteomics reveal alarmins as amplifiers of tissue pathology and
inflammation after spinal cord injury. Sci Rep 2016, 6: 21607.

[39] Chen KB, Uchida K, Nakajima H, Yayama T, Hirai T, Rodriguez Guerrero A, Kobayashi S, Ma WY, Liu SY, Zhu P, Baba H: High-mobility group box-1 and its receptors contribute to proinflammatory response in the acute phase of spinal cord injury in rats. Spine (Phila Pa 1976) 2011, 36(25): 2122-9.

[40] Papatheodorou A, Stein A, Bank M, Sison CP, Davies P, Bloom O: High-Mobility Group Box 1 (HMGB1) Is Elevated Systemically in Persons with Acute or Chronic Traumatic Spinal Cord Injury. J Neurotrauma 2017, 34(3): 746-754.

[41] Yang J, Liu X, Zhou Y, Wang G, Gao C, Su Q: Hyperbaric oxygen alleviates experimental (spinal cord) injury by downregulating HMGB1/NF-kappaB expression. Spine (Phila Pa 1976) 2013, 38(26): E1641-8.

[42] Sun Y, Liu B, Zheng X, Wang D: Notoginsenoside R1 alleviates lipopolysaccharide-triggered PC-12 inflammatory damage via elevating microRNA-132. Artif Cells Nanomed Biotechnol 2019, 47(1): 1808-1814.

[43] Wang Y, Yuan Y, Gao Y, Li X, Tian F, Liu F, Du R, Li P, Wang F, Xu S, Wu X, Wang C: MicroRNA-31 regulating apoptosis by mediating the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in treatment of spinal cord injury. Brain Dev 2019.

[44] Xu Z, Zhang K, Wang Q, Zheng Y: MicroRNA124 improves functional recovery and suppresses Bax-dependent apoptosis in rats following spinal cord injury. Mol Med Rep 2019, 19(4): 2551-2560.

[45] Zou Y, Kong M: Tetrahydroxy stilbene glucoside alleviates palmitic acid-induced inflammation and apoptosis in cardiomyocytes by regulating miR-129-3p/Smad3 signaling. Cell Mol Biol Lett 2019, 24: 5.

[46] Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundback P, Valdes-Ferrer SI, Olofsson PS, Kalb T, Roth J, Zou Y, Erlundsson-Harris H, Yang H, Ting JP, Wang H, Andersson U, Antoine DJ, Hotamisligil GS, Tracey KJ: Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012, 488(7413): 670-4.

[47] Avgousti DC, Herrmann C, Kulej K, Pancholi NJ, Sekulic N, Petrescu J, Molden RC, Blumenthal D, Paris AJ, Reyes ED, Ostapchuk P, Hearing P, Seeholzer SH, Worthen GS, Black BE, Garcia BA, Weitzman MD: A core viral protein binds host nucleosomes to sequester immune danger signals. Nature 2016, 535(7610): 173-7.

[48] Zhu X, Park J, Golinski J, Qiu J, Whalen MJ: Role of Akt and mammalian target of rapamycin in functional outcome after concussive brain injury in mice. J Cereb Blood Flow Metab 2014, 34(9): 1531-9.

[49] Fang P, Schachner M, Shen YQ: HMGB1 in development and diseases of the central nervous system. Mol Neurobiol 2012, 45(3): 499-506.

[50] Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al.: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995, 270(43): 25752-61.

[51] Liu M, Li C, Zhao GQ, Lin J, Che CY, Xu Q, Wang Q, Xu R, Niu YW: Boxb
mediate BALB/c mice corneal inflammation through a TLR4/MyD88-dependent signaling pathway in Aspergillus fumigatus keratitis. Int J Ophthalmol 2018, 11(4): 548-552.

[52] Kang N, Hai Y, Yang J, Liang F, Gao CJ: Hyperbaric oxygen intervention reduces secondary spinal cord injury in rats via regulation of HMGB1/TLR4/NF-kappaB signaling pathway. Int J Clin Exp Pathol 2015, 8(2): 1141-53.

[53] Wang S, Chen Y, Yu X, Lu Y, Wang H, Wu F, Teng L: miR-129-5p attenuates cell proliferation and epithelial mesenchymal transition via HMGB1 in gastric cancer. Pathol Res Pract 2019, 215(4): 676-682.

[54] Li G, Xie J, Wang J: Tumor suppressor function of miR-129-5p in lung cancer. Oncol Lett 2019, 17(6): 5777-5783.

[55] Liu AH, Wu YT, Wang YP: MicroRNA-129-5p inhibits the development of autoimmune encephalomyelitis-related epilepsy by targeting HMGB1 through the TLR4/NF-κB signaling pathway. Brain Res Bull 2017, 132 139-149.
Figure Legends

Figure 1 miR-129-5p was downregulated in spinal cord of SCI rats. (A) The BBB scores at 1, 3, 7, 14, 21 and 28 days after SCI were shown for all groups of mice. (B) Cresyl violet staining was used to assess spared tissue following behavioral analyses at 28 days post-injury. (C) Spinal cord water content was assessed using wet-to-dry weight method. (D) Heatmap of normalized expression levels of miRNAs in spinal cord tissues from SCI and sham rats. (E) qRT-PCR was performed to determine the expression levels of miR-129-5p in spinal cord tissues from mice at 1, 7, 14, 21 and 28 days after SCI. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01 vs. Sham group.

Figure 2 Agomir-miR-129-5p improves recovery of SCI mice by reducing apoptosis. The mice were subjected to SCI and then treated with agomir-miR-129-5p/agomir-NC (50 μL/d, 100 nmol/mL) for 3 days (0, 1, and 2 days) via intrathecal injection starting 15 min after contusion SCI. At indicated time, the animals were sacrificed and subsequently, a 10 mm long segment of the spinal cord was harvested for further experiments. (A) qRT-PCR was performed to determine the expression levels of miR-129-5p in spinal cord tissues at 1, 3, 7, 14 and 28 days after agomir-129-5p injection. (B) The BBB scores at 1, 3, 7, 14, 21 and 28 days after SCI were shown for all groups of mice. (C) Cresyl violet staining was used to assess spared tissue following behavioral analyses at 28 days post-injury. (D) Spinal cord water content was assessed using wet-to-dry weight method. (E) IHC analysis of cleaved caspase-3 at 7 days post-injury in spinal cord tissues. (F) The protein expressions of Bcl-2, Bax, cleaved caspase-3 and cleaved PARP were measured by Western Blot. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01 vs. Sham group; ##p < 0.01 vs. SCI + agomir-NC group.

Figure 3 miR-129-5p inhibited the inflammatory response in SCI mice. The mice were subjected to SCI and then treated with agomir-miR-129-5p/agomir-NC (50 μL/d, 100 nmol/mL) for 3 days (0, 1, and 2 days) via intrathecal injection starting 15 min after SCI. At indicated time, the animals were sacrificed, and subsequently serum samples were collected for detection of production of inflammatory factors. The levels of TNF-α (A), IL-6 (B), IL-1β (C), and IL-10 (D) in serum of mice were measured by ELISA kits. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01 vs. Sham group; ##p < 0.01 vs. SCI + agomir-NC group.

Figure 4 Overexpression of miR-129-5p suppressed inflammatory response and apoptosis in SCI cell model. (A) BV-2 cells were treated with different concentrations of LPS (10, 100 and 1000 ng/ml) for 24 h, and the expression of miR-129-5p was detected by qRT-PCR analysis. (B) Agomir-miR-129-5p was added to the cultured BV-2 cells 4 h prior to LPS treatment and incubated for 24 h, and then the transfected efficiency of agomir-miR-129-5p was detected by qRT-PCR analysis. (C) Activity of
caspase-3 was measured using a caspase-3 activity assay kit. (D) The protein expression level of caspase-3 in BV-2 cells was detected by IFA. (E-H) The expressions of TNF-α, IL-6, IL-1β and IL-10, were measured by ELISA analysis. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01 vs. Control group; ##p < 0.01 vs. LPS + agomir-NC group.

Figure 5 HMGB1 is a direct target of miR-129-5p in BV-2 cells. (A) Putative binding site of miR-129-5p and HMGB1 with mut and wt 3’-UTRs. (B) Luciferase assay of BV-2 cells co-transfected with firefly luciferase constructs containing the HMGB1 wild-type or mutated 3’-UTRs and agomir-miR-129-5p or agomir-NC, as indicated (n = 3). Data represent the mean ± SD of three independent experiments. **p < 0.01 vs. agomir-NC group. (C) The protein levels of HMGB1 were detected by Western Blot after agomir-miR-129-5p transfection. (D) BV-2 cells were treated with different concentrations of LPS (10, 100 and 1000 ng/ml) for 24 h, and the expression of HMGB1 was detected by qRT-PCR analysis. (E) The protein expression levels of HMGB1, TLR4, p-p65 and total p65 were detected by Western Blot analysis. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01 vs. Control group; ##p < 0.01 vs. LPS + agomir-NC group.

Figure 6 miR-129-5p protects BV-2 cells from LPS-induced apoptosis and inflammatory response by targeting HMGB1. Agomir-miR-129-5p and pcDNA-HMGB1 were co-transfected into the cultured BV-2 cells 4 h prior to LPS treatment, and incubated for 24 h, then cells were harvested for next experiments. (A) The transfected efficiency of pcDNA-HMGB1 was determined by Western Blot. (B) The protein expression level of caspase-3 was detected by IFA in BV-2 cells. (C) Activity of caspase-3 was measured using a commercial kit. (D-G) The expressions of TNF-α, IL-6, IL-1β and IL-10 were measured by ELISA analysis. Data represent the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01 vs. LPS group; ##p < 0.01 vs. LPS + agomir-miR-129-5p group.
A

B

LPS

LPS + agomir-miR-129-5p

LPS + agomir-miR-129-5p + pcDNA-HMGB1

C

D

E

G

Bioscience Reports. This is an Accepted Manuscript. You are encouraged to use the Version of Record that, when published, will replace this version. The most up-to-date version is available at https://doi.org/10.1042/BSR20193315